Moderna Flu Shot Fight: FDA Set to Decide - What Happens Next?!

Well, folks, it looks like we might be getting a new weapon in the fight against the dreaded flu. Moderna just announced that the FDA will *finally* be considering their application for a novel Influenza vaccine, specifically designed for us older folks. This comes after a bit of a public kerfuffle between the company and the agency, which, let's be honest, isn't something you see every day.

Moderna Flu Shot Fight: FDA Set to Decide - What H...

The heart of the matter was a pretty massive clinical trial—we're talking 40,000 participants—that seemed to show Moderna's new vaccine offering better protection against the flu in adults over 50, compared to the standard vaccines we're used to. Pretty exciting stuff! But the FDA initially balked, issuing a "refusal to file" letter. Apparently, the trial didn't include a specific brand of vaccine that's often recommended for those 65 and older.

Now, I'm no scientist, but it seems like that omission raised some eyebrows. The FDA, under Health Secretary Robert F. Kennedy Jr., seems to be taking a much harder look at vaccines, especially those using mRNA technology. Kennedy Jr. hasn't exactly been shy about his skepticism toward mRNA vaccines, which adds another layer of intrigue to this whole situation.

Think about it: In the last year, we've seen revised recommendations on COVID-19 vaccines, added warnings to the two main mRNA-based vaccines for COVID, and even some changes to the FDA advisory panel. It's clear that the FDA is operating under a different lens these days. Whether that's a good thing or a bad thing in the long run is still up for debate, honestly.

Moderna, understandably, is optimistic. They're hoping to have the vaccine available later this year, and they've also submitted applications for approval in Europe, Canada, and Australia. The FDA has set August 5th as the target date for a decision. So, we'll be watching closely to see what happens. A new, potentially more effective flu vaccine could be a real game-changer, especially for those of us who are a little more vulnerable to the virus. Fingers crossed that it gets the green light!

*(Editor's note: The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.)*